uniQure N.V. (NASDAQ:QURE) Given Average Rating of “Buy” by Analysts

Shares of uniQure N.V. (NASDAQ:QURE) have been assigned an average recommendation of “Buy” from the eleven research firms that are presently covering the company, Marketbeat reports. Two analysts have rated the stock with a hold rating, seven have issued a buy rating and two have assigned a strong buy rating to the company. The average twelve-month target price among analysts that have updated their coverage on the stock in the last year is $37.4545.

QURE has been the subject of a number of research reports. Wall Street Zen upgraded uniQure from a “sell” rating to a “hold” rating in a report on Saturday, August 2nd. Guggenheim reiterated a “buy” rating and issued a $28.00 price target on shares of uniQure in a report on Monday, May 12th. HC Wainwright reiterated a “buy” rating and issued a $70.00 price target on shares of uniQure in a report on Thursday, May 29th. Mizuho upgraded uniQure from a “neutral” rating to an “outperform” rating and set a $30.00 price target for the company in a report on Thursday, August 14th. Finally, Chardan Capital lowered their price target on uniQure from $38.00 to $35.00 and set a “buy” rating for the company in a report on Tuesday, July 29th.

Insider Buying and Selling at uniQure

In other uniQure news, Director Robert Gut sold 3,336 shares of the stock in a transaction on Friday, June 20th. The stock was sold at an average price of $14.45, for a total transaction of $48,205.20. Following the sale, the director owned 56,879 shares of the company’s stock, valued at approximately $821,901.55. This trade represents a 5.54% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Madhavan Balachandran sold 2,112 shares of the stock in a transaction on Friday, June 20th. The shares were sold at an average price of $14.45, for a total value of $30,518.40. Following the sale, the director directly owned 37,697 shares in the company, valued at $544,721.65. This trade represents a 5.31% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 22,144 shares of company stock worth $322,426. 4.79% of the stock is currently owned by company insiders.

Institutional Trading of uniQure

Several hedge funds and other institutional investors have recently bought and sold shares of QURE. Tower Research Capital LLC TRC lifted its holdings in shares of uniQure by 358.0% during the 2nd quarter. Tower Research Capital LLC TRC now owns 7,085 shares of the biotechnology company’s stock valued at $99,000 after purchasing an additional 5,538 shares during the last quarter. KLP Kapitalforvaltning AS purchased a new stake in shares of uniQure during the 2nd quarter valued at $117,000. Mraz Amerine & Associates Inc. purchased a new stake in shares of uniQure during the 1st quarter valued at $106,000. Teacher Retirement System of Texas purchased a new stake in shares of uniQure during the 2nd quarter valued at $151,000. Finally, Wells Fargo & Company MN lifted its holdings in shares of uniQure by 13.9% during the 4th quarter. Wells Fargo & Company MN now owns 12,294 shares of the biotechnology company’s stock valued at $217,000 after purchasing an additional 1,503 shares during the last quarter. Institutional investors own 78.83% of the company’s stock.

uniQure Trading Up 0.5%

QURE opened at $15.55 on Friday. The stock has a market cap of $853.18 million, a price-to-earnings ratio of -3.97 and a beta of 0.11. The stock’s 50 day moving average price is $14.55 and its 200-day moving average price is $13.64. uniQure has a one year low of $4.45 and a one year high of $19.18. The company has a debt-to-equity ratio of 1.53, a quick ratio of 9.98 and a current ratio of 9.98.

uniQure (NASDAQ:QURE) last announced its quarterly earnings results on Tuesday, July 29th. The biotechnology company reported ($0.69) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.89) by $0.20. The firm had revenue of $5.26 million during the quarter, compared to analyst estimates of $5.00 million. uniQure had a negative return on equity of 1,010.74% and a negative net margin of 1,387.98%. On average, equities analysts forecast that uniQure will post -3.75 EPS for the current year.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.